Board of Governors

Lee Byberg, MBA, Board Chair of Syntiron

Lee Byberg is the Chief Operating Officer and Chief Financial Officer of Rivendell Worldview Education Company, LLC. Lee earned his Bachelor of Science in Business Administration and his MBA from the Carlson School of Management at the University of Minnesota. Lee has over 20 years of U.S. and international business experience in the energy, agricultural and biotechnology sectors. He specializes in business growth and fundraising.

Terri Wasmoen, PhD

Terri is the General Manager of Epitopix LLC and joined the Board of Directors for Syntiron in 2016.  Terri has a Ph.D. in Immunology from the Mayo Graduate School of Medicine and has worked in both human and veterinary vaccine development for several different companies.  She has over 30 years of industrial research experience focused in the areas of infectious disease research, vaccine development, diagnostics, and antibody therapeutics.  Prior to joining Epitopix, Terri was the Associate Vice President of Research for Merck Animal Health, where she led  multi-national teams that successfully registered veterinary vaccines in more than 50 different countries.  Terri is the inventor on several issued patents and widely published.

Patricia Tam, PhD

Patty Tam is the Senior Scientific Director at Syntiron. Patty has more than 30 years of experience in microbiology, immunology, and molecular biology. Patty earned her Ph.D. in Bacteriology from the University of Wisconsin, Madison. She was a member of the faculty at the University of Minnesota Medical School, where her research focused on the link between infection and the pathogenesis of chronic inflammatory and autoimmune disease. She also served as CSO of an early stage diagnostics company and, as a consultant, led projects for a variety of large and small pharma companies. Patty joined Syntiron in 2011, where she managed a $4.4 MM defense department contract and currently directs the E. coli vaccine program. She is an inventor on several patents, and her professional activities have included peer review for major scientific journals and study sections at the NIH and Arthritis Foundation as well as scientific and business advisory board memberships.

Lisa Herron-Olson, PhD

Lisa Herron-Olson is the Chief Operating Officer at Syntiron. Lisa joined Syntiron in 2005 as the Program Manager for the Staphylococcus aureus vaccine development program and has continued to manage this project as the Principal Investigator for several NIH grants and a 3-year research collaboration with Sanofi Pasteur. She is the inventor on several issued and pending patents related to the vaccine technology platform. Lisa earned her PhD in Comparative Molecular Bioscience with a minor in Bioinformatics from the University of Minnesota in 2005. She also currently serves on the Board of Directors for the Twin Cities biotechnology startup ecosystem University Enterprise Laboratories.